Iloprost inhalation solution for the treatment of pulmonary arterial hypertension

Bibliography

• RUBIN LJ: Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest (2004) 126(1 Suppl.): 7S–10S.
   Google Scholar
• ••Evidence-based consensus expertguidelines for diagnosis and management of PAH.
   Google Scholar
• [NO AUTHORS LISTED]: Proceedings of the 3rd World Symposium on pulmonary arterial hypertension. Venice, Italy June 23–25 2003.1 Am. Coll. Cardiol (2004) 43(12 Suppl. S):1S–905.
   Google Scholar
• MANDEGAR M, FUNG YC, HUANG W et al.: Cellular and molecular mechanisms of pulmonary vascular remodeling: role in the development of pulmonary hypertension. Microvasc. Res. (2004) 68(2):75–103.
   PubMed Web of Science ®Google Scholar
• HUMBERT M, MORRELL NW, ARCHER SL et al.: Cellular and molecular pathobiology of pulmonary arterial hypertension. J. Am. Coll. Cardiol (2004) 43(12 Suppl. S):135–245.
   Google Scholar
• CHRISTMAN BW, MCPHERSON CD, NEWMAN JH et al.: An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary. N Engl J. Med. (1992) 327(2):70–75.
   PubMed Web of Science ®Google Scholar
• HAYWOOD GA, ADAMS KF JR, GHEORGHIADE M, MCKENNA WJ: Is there a role for epoprostenol in the management of heart failure?. J. CardioL (1995) 75(3):44A-50A.
   Google Scholar
• OLSCHEWSKI H, GHOFRANI HA, WALMRATH D et al.: Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am. J. Respir. Crit. Care Med. (1999) 160(2):600–607.
   PubMed Web of Science ®Google Scholar
• SEREGI A, SCHOBERT A, G: The stable prostacyclin-analogue, iloprost, unlike prostanoids and leukotrienes, potently stimulates cyclic adenosine monophosphate synthesis of primary astroglial cell cultures.. PharmacoL (1988) 40(6):437–438.
   Google Scholar
• LEIGH PJ, CRAMP Wk MACDERMOT J: Identification of the prostacyclin receptor by radiation inactivation. J. Biol. Chem. (1984) 259(20):12431–12436.
   PubMed Web of Science ®Google Scholar
• VANE JR, BOTTING RM: profile of prostacyclin.. J. CardioL (1995) 75(3):3A-10A.
   Google Scholar
• SANIABADI AR, BELCH JJ, LOWE GD, BARBENEL JC, FORBES CD: Comparison of inhibitory actions of prostacyclin and a new prostacyclin analogue on the aggregation of human platelet in whole blood. Haemostasis (1987) 17(3):147–153.
   PubMedGoogle Scholar
• WHARTON J, DAVIE N, UPTON PD, YACOUB MH, POLAK JM, NW: Prostacyclin differentially inhibit growth of distal and proximal human pulmonary artery smooth muscle cells. Circulation (2000) 102(25):3130–3136.
   PubMed Web of Science ®Google Scholar
• CLAPP LH, FINNEY P, TURCATO S, TRAN S, RUBIN LJ, TINKER A: Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery.. J. Respir. Cell Md. Biol. (2002) 26(2):194–201.
   Google Scholar
• LI RC, CINDROVA-DAVIES T, SKEPPER JN, SELLERS LA: Prostacyclin induces apoptosis of vascular smooth muscle cells by a cAMP-mediated inhibition of extracellular signal-regulated kinase activity and can counteract the mitogenic activity of endothelin-1 or basic fibroblast factor.. Res. (2004) 94(6):759–767.
   Google Scholar
• OLSCHEWSKI H, ROSE F, E, GHOFRANI HA: pathophysiology and therapy of pulmonary hypertension. J. Lab. Clin. Med. (2001) 138(0:367–377.
   PubMedGoogle Scholar
• SCHERMULY RT, KREISSELMEIER KP, GHOFRANI HA et al.: Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension. Circ. Res. (2004) 94(8):1101–1108.
   PubMed Web of Science ®Google Scholar
• IOANNOU P, TALESNIK J: Platelet antiaggregatory substances inhibit arachidonic acid induced coronary constriction. Can. J. Physiol Pharmacol (1986) 64(4):398–405.
   PubMed Web of Science ®Google Scholar
• MULLER B, SCHMIDTKE M,WITT W: Action of the stable prostacyclin analogue iloprost on microvascular tone and permeability in the hamster cheek pouch. Prostaglandins Leukot. Med. (1987) 29(2-3):187–198.
   PubMedGoogle Scholar
• SCHULZ BG, MULLER B: Iloprost antagonizes endothelin-induced vasoconstriction in macro- and microcirculation. Eicosanoids (1990) 3(3):135–138.
   PubMedGoogle Scholar
• OZAKI H, ABE A, UEHIGASHI Yet al: Effects of a prostaglandin 12 analog iloprost on cytoplasmic Ca2+ levels and muscle contraction in isolated guinea pig aorta. Jpn. J. Pharmacol (1996) 71(3):231–237.
   PubMedGoogle Scholar
• SCHUBERT R, SEREBRYAKOV VN, MEWES H, HOPP HH: Iloprost dilates rat small arteries: role of K(ATP)- and K(Ca)-channel activation by cAMP-dependent protein kinase. Am. J. Physiol (1997) 272(3 Pt 2):H1147–H1156.
   Google Scholar
• COWLEY AJ, HEPTINSTALL S, HAMPTON JR: Effects of prostacyclin and of the stable prostacyclin analogue ZK 36374 on forearm blood flow and blood platelet behaviour in man.. Haemost. (1985) 53(1):90–94.
   Google Scholar
• GROOM TM, GAUTIERI RF: Influence of a stable prostacyclin analogue (iloprost) and cyclooxygenase inhibition on angiotensin-II in the perfused human placenta. Res. Commun. Chem. Pharmacol (1989) 66(1):21–32.
   PubMedGoogle Scholar
• GRUNER S, BECKER K, VOLK HD, VON BAEHR R, LANGKOPF B, FORSTER W: Immunomodulatory effects of iloprost in vitro and in vivo comparison various prostaglandins. Clin. Biol. Res. (1987) 242:345–350.
   PubMedGoogle Scholar
• MULLER B, SCHMIDTKE M, WITT W: Adherence of leucocytes to electrically damaged venules in vivo. Effects of iloprost PGE1, indomethacin, forskolin 755 C, sulotroban, hirudin, and thrombocytopenia. Eicosanoids (1988) 1(1):13–17.
   Google Scholar
• NEY P, HECKER G, SCHRODER H, SCHROR K: Potent inhibition of leukotriene (LT) B4 release from human polymorphonuclear leukocytes (PMN) by the PGE1-analogue OP-1206.. Biochim. Acta (1988) 47(10–11):5186–5189.
   Google Scholar
• KORBUT R, TRABKA-JANIK E, GRYGLEWSKI RJ: Cytoprotection of human polymorphonuclear leukocytes by stimulators of adenylate and guanylate cyclases. Eur. j Pharmacol (1989) 165(1):171–172.
   PubMed Web of Science ®Google Scholar
• MAZZONE A. MAZZUCCHELLI I, FOSSATI G et al.: Iloprost effects on phagocytes in patients suffering from ischaemic diseases: in vivo evidence for down-regulation of alpha M beta 2 integrin. Eur. J. Clin. Invest. (1996) 26(10):860–866.
   Google Scholar
• KAPPA JR, HORN MK III, FISHER CA, COTTRELL ED, ELLISON N, ADDONIZIO VP Jr: Efficacy of iloprost (ZK36374) versus aspirin in preventing heparin-induced platelet activation during cardiac operations. J. Thorac. Cardiovasc. Surg. (1987) 94(3):405–413.
   PubMed Web of Science ®Google Scholar
• WITT W, MULLER B: Antithrombotic profile of iloprost in experimental models of in vivo platelet aggregation and thrombosis. Adv. Prostaglandin Thromboxane Leukot. Res. (1987) 17A:279–284.
   PubMedGoogle Scholar
• SHANBERGE JN, KAJIWARA Y, QUATTROCIOCCHI-LONGE T: Effect of aspirin and iloprost on adhesion of platelets to intact endothelium in vivo. J. Lab. Clin. Med. (1995) 125(1):96–101.
   PubMed Web of Science ®Google Scholar
• OLSCHEWSKI H, ROHDE B, BEHR J et al.: Pharmacodynamics and pharmacokinetics of inhaled iloprost, aerosolized by three different devices, in severe pulmonary hypertension. Chest (2003) 124(4):1294–1304.
   PubMed Web of Science ®Google Scholar
• SCHERMULY RT, SCHULZ A, GHOFRANI HA et al.: Pharmacokinetics and metabolism of infused versus inhaled iloprost in isolated rabbit lungs.. Pharmacol Exp. Ther. (2002) 303(2):741–745.
   Google Scholar
• KRAUSE W, KRAIS T: Pharmacokinetics and pharmacodynamics of radio-labeled iloprost in elderly volunteers.. J. Clin. Pharmacol (1987) 32(0:597–605.
   Google Scholar
• KRAUSE W, HUMPEL M, HOYER BA: Biotransformation of the stable prostacyclin analogue, iloprost, in the rat. Metab. Dispos. (1984) 12(5):645–651.
   PubMed Web of Science ®Google Scholar
• OLSCHEWSKI H, WALMRATH D, SCHERMULY R, GHOFRANI A, GRIMMINGER F, SEEGER W: Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann. Intern. Med. (1996) 124(9):820–824.
   PubMed Web of Science ®Google Scholar
• HOEPER MM, OLSCHEWSKI H, GHOFRANI HA et al: A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group. J. Am. Coll Cardiol (2000) 35(1):176–182.
   PubMed Web of Science ®Google Scholar
• OLSCHEWSKI H, GHOFRANI HA, SCHMEHL T et al: Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH Study Group. Ann. Intern. Med. (2000) 132(0:435–443.
   PubMedGoogle Scholar
• GESSLER T, SCHMEHL T, HOEPER MM et al: Ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension. Eur. Respir J. (2001) 17(1):14–19.
   PubMed Web of Science ®Google Scholar
• OLSCHEWSKI H, SIMONNEAU G, GALIE N et al.: Inhaled iloprost for severe pulmonary hypertension. N Engl J. Med. (2002) 347(5):322–329. multi-centre trial demonstrating efficacy of inhaled iloprost in PAH.
   Google Scholar
• PETTERSEN E, MORSTOL TH, VEGSUNDVAG JA: Long-term echocardiographic follow-up of a patient with primary pulmonary hypertension receiving iloprost inhalations.. J. Echocardiogr. (2005) 6(1):67–71.
   Google Scholar
• LEUCHTE HH, SCHWAIBLMAIR M, BAUMGARTNER RA, NEUROHR CF, KOLBE T, BEHR J: Hemodynamic response to sildenafil, nitric oxide, and iloprost in primary pulmonary hypertension. Chest (2004) 125(2):580–586.
   PubMed Web of Science ®Google Scholar
• HALANK M, MARX C, MIEHLKE S, HOEFFKEN G: Use of aerosolized inhaled iloprost in the treatment of portopulmonary hypertension. J. Gastroenterol (2004) 39(12):1222–1223.
   PubMed Web of Science ®Google Scholar
• GHOFRANI HA, FRIESE G, T et al.: Inhaled iloprost is a potent acute pulmonary vasodilator in HIV-related severe pulmonary hypertension. Eur. Respir. (2004) 23(2):321–326.
   PubMed Web of Science ®Google Scholar
• OPITZ CF, WENSEL R, BETTMANN M et al.: Assessment of the vasodilator response in primary pulmonary hypertension. Comparing prostacyclin and iloprost administered by either infusion or inhalation. Eur. Heart J. (2003) 24(4):356–365.
   Google Scholar
• LEUCHTE HH, BAUMGARTNER RA, BEHR J: Treatment of severe pulmonary hypertension with inhaled iloprost. Ann. Intern. Med. (2003) 139(4):306.
   PubMed Web of Science ®Google Scholar
• KRAMM T, EBERLE B, KRUMMENAUER F, GUTH S, H, MAYER E: Inhaled iloprost in patients with chronic thromboembolic pulmonary hypertension: effects before and after pulmonary thromboendarterectomy. Ann. Thorac. Surg. (2003) 76(3):711–718.
   PubMed Web of Science ®Google Scholar
• HALLIOGLU 0, DILBER E, A: Comparison of acute hemodynamic effects of aerosolized and intravenous iloprost in secondary pulmonary hypertension in children with congenital heart disease. Am. J. CardioL (2003) 92(8):1007–1009.
   PubMed Web of Science ®Google Scholar
• FRUHWALD FM, KJELLSTROM B, PERTHOLD Wet al.: Continuous hemodynamic monitoring in pulmonary hypertensive patients treated with inhaled iloprost. Chest (2003) 124(1):351–359.
   Google Scholar
• EHLEN M, WIEBE B: Iloprost in persistent pulmonary hypertension of the newborn. CardioL Young (2003) 13(4):361–363.
   PubMed Web of Science ®Google Scholar
• GHOFRANI HA, -WIEDEMANN R, ROSE F et al.: Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann. Intern. Med. (2002) 136(7):515–522.
   PubMed Web of Science ®Google Scholar
• BLUMBERG FC, RIEGGER GA, PFEIFER M: Hemodynamic effects of aerosolized iloprost in pulmonary hypertension at rest and during exercise. Chest (2002) 121(5):1566–1571.
   PubMed Web of Science ®Google Scholar
• WILKENS H, GUTH A, KONIG Jet aL: Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation (2001) 104(11):1218–1222.
   PubMed Web of Science ®Google Scholar
• WENSEL R, OPITZ CF, EWERT R, BRUCH L, KLEBER FX: Effects of iloprost inhalation on exercise capacity and ventilatory efficiency in patients with primary pulmonary hypertension. Circulation (2000) 101(20):2388–2392.
   PubMed Web of Science ®Google Scholar
• HOEPER MM, SCHWARZE M, EHLERDING S et aL: Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N EngL J. Med. (2000) 342(25):1866–1870.
   PubMed Web of Science ®Google Scholar
• OLSCHEWSKI H: Safety, dosing, and clinical benefit of 2-year therapy with inhaled iloprost. American Thoracic Society Meeting. San Diego, USA (2005) [A57] [Poster: K29].
   Google Scholar
• OPITZ CF, WENSEL R, -WINKLER J et al.: Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Eur. Heart. J. (2005) [Epub ahead of print].
   Google Scholar
• D'ALONZO GE, BARST RJ, AYRES SM et aL: Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.. Intern. Med. (1991) 115(5):343–349.
   Google Scholar
• CUIPER LL, PRICE PV, BW: Systemic and pulmonary hypertension after abrupt cessation of prostacyclin: role of thromboxane A2. J. Appl. PhysioL (1996) 80(1):191–197.
   PubMed Web of Science ®Google Scholar
• SCHULZE-NEICK I, WERNER H, PENNY DJ, ALE)U-MESKISHVILI V, LANGE PE: Acute ventilatory restriction in children after weaning off inhaled nitric oxide: relation to rebound pulmonary hypertension. Intensive Care Med. (1999) 25(1):76–80.
   PubMed Web of Science ®Google Scholar
• PEARL JM, NELSON DP, RAAKE JL et aL: Inhaled nitric oxide increases endothelin-1 levels: a potential cause of pulmonary hypertension. Crit. Care Med. (2002) 30(1):89–93.
   PubMed Web of Science ®Google Scholar
• NIKANDER K, ARHEDEN L, DENYER J, COBOS N: Parents' adherence with nebulizer treatment of their children when using an adaptive aerosol delivery (AAD) system.. Aerosol Med. (2003) 16(3):273–281.
   Google Scholar
• NIKANDER K, DENYER J, SMITH N, WOLLMER P: Breathing patterns and aerosol delivery: impact of regular human patterns, and sine and square waveforms on rate of delivery./ Aerosol Med. (2001) 14(3):327–333.
   Google Scholar
• NIKANDER K, TURPEINEN M, WOLLMER P: Evaluation of pulsed and breath-synchronized nebulization of budesonide as a means of reducing nebulizer wastage of drug. Pediatr. PulmonoL (2000) 29(2):120–126.
   PubMed Web of Science ®Google Scholar
• NIKANDER K, AGERTOFT L, PEDERSEN S: Breath-synchronized nebulization diminishes the impact of patient-device interfaces (face mask or mouthpiece) on the inhaled mass of nebulized budesonide.. Asthma (2000) 37(5):451–459.
   Google Scholar
• HOEPER MM, TAHA N, A, GATZKE R, SPIEKERKOETTER E: Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids.. Respir. J. (2003) 22(2):330–334.
   Google Scholar
• GHOFRANI HA, ROSE F, SCHERMULY RT et aL: Oral as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J. Am. Coll. CardioL (2003) 42(1):158–164.
   PubMed Web of Science ®Google Scholar